FDA Extends Reproductive Drugs Advisory Panel
Published Date: 3/18/2026
Notice
Summary
The FDA is renewing its Obstetrics, Reproductive and Urologic Drugs Advisory Committee for two more years, keeping it active until March 23, 2028. This committee helps make sure medicines related to pregnancy, reproductive health, and urology are safe and effective. Doctors, patients, and drug makers all benefit from this continued expert advice, with no new costs or changes in how the committee works.
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in